Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
33 drugs across 16 manufacturers|25 Generic,8 Brand
The Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class contains 33 NDCs from 16 manufacturers (25 generic, 8 brand), at an average NADAC of $25.03 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
33
25G / 8B
Manufacturers
16
Avg $25.0302/unit
Avg 7d Change
-0.01%
Across 24 drugs with changes
7d Activity
of 33 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Frequently Asked Questions
How many drugs are in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class?
The Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class contains 33 NDCs from 16 manufacturers — 25 generic and 8 brand products.
What is the average price of Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor drugs?
The average NADAC for the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class is $25.0302 per unit across 33 NDCs.
Is generic cheaper than brand in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class?
The average generic NADAC in this class is $8.2752 per unit, versus $77.3896 for brand — generic is about 89% cheaper on average.
Which manufacturers make Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor drugs?
16 manufacturers make drugs in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class. Ranked by number of NDCs, the largest are Mylan Pharmaceuticals Inc. (3), Janssen Products LP (3), Macleods Pharmaceuticals Limited (3), Camber Pharmaceuticals Inc. (3), Aurobindo Pharma Limited (3).
How has Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor pricing changed recently?
Over the past 7 days, 14 NDCs in this class rose and 10 fell, with a class-wide average change of -0.0%.
Manufacturer Breakdown
16 manufacturers producing drugs in this therapeutic class(2 pricing outliers)
and 4 more manufacturers